Revealing the invisible disease causing heart attacks

Our award winning technology is built on almost a decade of academic research from leading institutes

We use commonly available imaging methods in new ways to reveal the features of coronary plaque that can cause heart attack

Coronary Artery Disease

>9M deaths globally p.a.
12% of deaths in AUS
30mins someone dies in AUS

Mosaic uses deep learning to rapidly analyse coronary CT angiography scans

This not only provides a detailed assessment of the coronary arteries and any plaque present, but also the microcalcification activity

Patients with high microcalcification activity have a 7-fold increased risk of heart attack[1]

Apricot uses deep learning and biomechanics to analyse intravascular optical coherence tomography (OCT) scans

This removes the manual processing needed to interpret OCT scans and also provides an assessment of the residual risk of heart attack after treatment

The software also determines the microcalcification activity of the patient

Logo for Western Australia Innovator of the Year 2021 - Rio Tinto Emerging Innovation Category Winner

Spun out from a decade research at University of Western Australia and Harry Perkins Institute of Medical Research

A team of biomedical engineers and cardiologist at VascLab have spent several years researching innovative ways improve the treatment of heart disease

In mid 2021 the company Navier Medical was spun out of a partnership between the Harry Perkins Institute of Medical Research and the University of Western Australia

Associate Professor Barry Doyle and his team created Navier Medical to commercialize the Apricot and Mosaic technology